<?xml version='1.0' encoding='utf-8'?>
<document id="27327872"><sentence text="Effects of berberine on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism."><entity charOffset="11-20" id="DDI-PubMed.27327872.s1.e0" text="berberine" /><entity charOffset="48-56" id="DDI-PubMed.27327872.s1.e1" text="losartan" /><pair ddi="false" e1="DDI-PubMed.27327872.s1.e0" e2="DDI-PubMed.27327872.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27327872.s1.e0" e2="DDI-PubMed.27327872.s1.e1" /></sentence><sentence text="Losartan and berberine (BBR) are often simultaneously used for the treatment of senile diabetic nephropathy in clinics"><entity charOffset="0-8" id="DDI-PubMed.27327872.s2.e0" text="Losartan" /><entity charOffset="13-22" id="DDI-PubMed.27327872.s2.e1" text="berberine" /><entity charOffset="24-27" id="DDI-PubMed.27327872.s2.e2" text="BBR" /><pair ddi="false" e1="DDI-PubMed.27327872.s2.e0" e2="DDI-PubMed.27327872.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27327872.s2.e0" e2="DDI-PubMed.27327872.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27327872.s2.e0" e2="DDI-PubMed.27327872.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27327872.s2.e1" e2="DDI-PubMed.27327872.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27327872.s2.e1" e2="DDI-PubMed.27327872.s2.e2" /></sentence><sentence text=" However, the potential herb-drug interaction between losartan and BBR is unknown"><entity charOffset="54-62" id="DDI-PubMed.27327872.s3.e0" text="losartan" /><entity charOffset="67-74" id="DDI-PubMed.27327872.s3.e1" text="BBR" /><pair ddi="false" e1="DDI-PubMed.27327872.s3.e0" e2="DDI-PubMed.27327872.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27327872.s3.e0" e2="DDI-PubMed.27327872.s3.e1" /></sentence><sentence text="" /><sentence text="This study investigates the influence of BBR on the pharmacokinetics of losartan and EXP3174, and investigates the effects of BBR on the metabolic stability of losartan"><entity charOffset="72-80" id="DDI-PubMed.27327872.s5.e0" text="losartan" /><entity charOffset="85-92" id="DDI-PubMed.27327872.s5.e1" text="EXP3174" /><entity charOffset="160-168" id="DDI-PubMed.27327872.s5.e2" text="losartan" /><entity charOffset="41-48" id="DDI-PubMed.27327872.s5.e3" text="BBR" /><entity charOffset="126-133" id="DDI-PubMed.27327872.s5.e4" text="BBR" /><pair ddi="false" e1="DDI-PubMed.27327872.s5.e3" e2="DDI-PubMed.27327872.s5.e3" /><pair ddi="false" e1="DDI-PubMed.27327872.s5.e3" e2="DDI-PubMed.27327872.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27327872.s5.e3" e2="DDI-PubMed.27327872.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27327872.s5.e3" e2="DDI-PubMed.27327872.s5.e4" /><pair ddi="false" e1="DDI-PubMed.27327872.s5.e3" e2="DDI-PubMed.27327872.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27327872.s5.e0" e2="DDI-PubMed.27327872.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27327872.s5.e0" e2="DDI-PubMed.27327872.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27327872.s5.e0" e2="DDI-PubMed.27327872.s5.e4" /><pair ddi="false" e1="DDI-PubMed.27327872.s5.e0" e2="DDI-PubMed.27327872.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27327872.s5.e1" e2="DDI-PubMed.27327872.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27327872.s5.e1" e2="DDI-PubMed.27327872.s5.e4" /><pair ddi="false" e1="DDI-PubMed.27327872.s5.e1" e2="DDI-PubMed.27327872.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27327872.s5.e4" e2="DDI-PubMed.27327872.s5.e4" /><pair ddi="false" e1="DDI-PubMed.27327872.s5.e4" e2="DDI-PubMed.27327872.s5.e2" /></sentence><sentence text="" /><sentence text="The pharmacokinetic profiles losartan and EXP3174 of orally administered losartan (10 mg/kg) with and without pretreatment with BBR (20 mg/kg) within 24 h were determined in Sprague-Dawley rats"><entity charOffset="29-37" id="DDI-PubMed.27327872.s7.e0" text="losartan" /><entity charOffset="42-49" id="DDI-PubMed.27327872.s7.e1" text="EXP3174" /><entity charOffset="73-81" id="DDI-PubMed.27327872.s7.e2" text="losartan" /><entity charOffset="128-135" id="DDI-PubMed.27327872.s7.e3" text="BBR" /><pair ddi="false" e1="DDI-PubMed.27327872.s7.e0" e2="DDI-PubMed.27327872.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27327872.s7.e0" e2="DDI-PubMed.27327872.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27327872.s7.e0" e2="DDI-PubMed.27327872.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27327872.s7.e0" e2="DDI-PubMed.27327872.s7.e3" /><pair ddi="false" e1="DDI-PubMed.27327872.s7.e1" e2="DDI-PubMed.27327872.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27327872.s7.e1" e2="DDI-PubMed.27327872.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27327872.s7.e1" e2="DDI-PubMed.27327872.s7.e3" /><pair ddi="false" e1="DDI-PubMed.27327872.s7.e2" e2="DDI-PubMed.27327872.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27327872.s7.e2" e2="DDI-PubMed.27327872.s7.e3" /></sentence><sentence text=" The inhibitory effects of BBR on the metabolic stability of losartan were investigated using rat liver microsomes"><entity charOffset="61-69" id="DDI-PubMed.27327872.s8.e0" text="losartan" /><entity charOffset="27-34" id="DDI-PubMed.27327872.s8.e1" text="BBR" /><pair ddi="false" e1="DDI-PubMed.27327872.s8.e1" e2="DDI-PubMed.27327872.s8.e1" /><pair ddi="false" e1="DDI-PubMed.27327872.s8.e1" e2="DDI-PubMed.27327872.s8.e0" /></sentence><sentence text="" /><sentence text="The Cmax (1" /><sentence text="26 ± 0" /><sentence text="37 versus 1" /><sentence text="96 ± 0" /><sentence text="45 mg/L) and the AUC(0-t) (8" /><sentence text="25 ± 0" /><sentence text="89 versus 12" /><sentence text="70 ± 1" /><sentence text="42 mg h/L) of losartan were significantly (p &lt; 0"><entity charOffset="14-22" id="DDI-PubMed.27327872.s18.e0" text="losartan" /></sentence><sentence text="05) increased by BBR compared to the control, while the Cmax (0"><entity charOffset="17-24" id="DDI-PubMed.27327872.s19.e0" text="BBR" /></sentence><sentence text="97 ± 0" /><sentence text="15 versus 0" /><sentence text="77 ± 0" /><sentence text="06 mg/L) of EXP3174 was significantly decreased compared to the control (p &lt; 0" /><sentence text="05)" /><sentence text=" The Tmax of losartan was prolonged from 0"><entity charOffset="13-21" id="DDI-PubMed.27327872.s25.e0" text="losartan" /></sentence><sentence text="41 ± 0" /><sentence text="12 to 0" /><sentence text="52 ± 0" /><sentence text="18 h, but the difference was not significant" /><sentence text=" However, the Tmax of EXP3174 was decreased significantly (p &lt; 0" /><sentence text="05) from 8" /><sentence text="14 ± 0" /><sentence text="36 to 3" /><sentence text="33 ± 0" /><sentence text="28 h" /><sentence text=" The metabolic stability of losartan was increased from 37"><entity charOffset="28-36" id="DDI-PubMed.27327872.s36.e0" text="losartan" /></sentence><sentence text="4 to 59" /><sentence text="6 min" /><sentence text="" /><sentence text="We infer that BBR might increase the plasma concentration of losartan and decrease the concentration of EXP3174 through inhibiting the activity of CYP3A4 or CYP2C9"><entity charOffset="61-69" id="DDI-PubMed.27327872.s40.e0" text="losartan" /><entity charOffset="14-21" id="DDI-PubMed.27327872.s40.e1" text="BBR" /><pair ddi="false" e1="DDI-PubMed.27327872.s40.e1" e2="DDI-PubMed.27327872.s40.e1" /><pair ddi="false" e1="DDI-PubMed.27327872.s40.e1" e2="DDI-PubMed.27327872.s40.e0" /></sentence><sentence text="" /></document>